Sugi Predict

Sugi Predict / Compounds / SCHEMBL1021968

SCHEMBL1021968

SCHEMBL1021968

C[C@H](Nc1ccc2cc3ccccc3cc2c1)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 6/20 0.49
▸ SMN1; SMN2 Q16637 4/20 0.49
▸ GAA P10253 2/20 0.49
▸ NPC1 O15118 5/20 0.47
▸ MAPT P10636 3/20 0.47
▸ ALDH1A1 P00352 3/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ MEN1 O00255 4/20 0.44
▸ KMT2A Q03164 4/20 0.44
▸ CYP1A2 P05177 2/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ HIF1A Q16665 1/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ POLB P06746 1/20 0.42
▸ LMNA P02545 3/20 0.42
▸ SLC1A3 P43003 1/20 0.42
▸ SLC1A2 P43004 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29928621 1.00 RAB9A (0.49) RAB9ASMN1; SMN2GAANPC1MAPT
SCHEMBL8624223 1.00 RAB9A (0.49) RAB9ASMN1; SMN2GAANPC1MAPT
SCHEMBL29350028 0.95 RAB9A (0.54) RAB9ASMN1; SMN2GAANPC1MAPT
SCHEMBL288854 0.95 RAB9A (0.54) RAB9ASMN1; SMN2GAANPC1MAPT
SCHEMBL29478375 0.95 RAB9A (0.54) RAB9ASMN1; SMN2GAANPC1MAPT
SCHEMBL43518 0.95 RAB9A (0.54) RAB9ASMN1; SMN2GAANPC1MAPT
SCHEMBL43517 0.95 RAB9A (0.54) RAB9ASMN1; SMN2GAANPC1MAPT
Hydrochloric Acid SCHEMBL2351803 0.93 RAB9A (0.53) RAB9ASMN1; SMN2GAANPC1MAPT
Hydrochloric Acid SCHEMBL2351807 0.93 RAB9A (0.53) RAB9ASMN1; SMN2GAANPC1MAPT
SCHEMBL27140016 0.86 AKR1B1 (0.50) RAB9ASMN1; SMN2GAANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111909242-B Polypeptide with high affinity and specific binding of beta-catenin protein and application and synthetic method thereof 西安交通大学医学院第一附属医院 2021-12-17 — — CN claimed
CN-111909242-A Polypeptide with high affinity and specific binding of beta-catenin protein and application and synthetic method thereof 西安交通大学医学院第一附属医院 2020-11-10 — — CN claimed
EP-1109831-B1 CYCTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES LYTIX BIOPHARMA AS (NO) 2011-01-12 — — EP claimed
CN-111909242-B Polypeptide with high affinity and specific binding of beta-catenin protein and application and synthetic method thereof 西安交通大学医学院第一附属医院 2021-12-17 — — CN disclosed
CN-111909242-B Polypeptide with high affinity and specific binding of beta-catenin protein and application and synthetic method thereof 西安交通大学医学院第一附属医院 2021-12-17 — — CN disclosed
WO-2021228967-A1 ACTIVE AND ORTHOGONAL HYBRID PYRROLYSYL tRNA NESTED BIO AB (SE) 2021-11-18 — — WO disclosed
CN-111909242-A Polypeptide with high affinity and specific binding of beta-catenin protein and application and synthetic method thereof 西安交通大学医学院第一附属医院 2020-11-10 — — CN disclosed
CN-111909242-A Polypeptide with high affinity and specific binding of beta-catenin protein and application and synthetic method thereof 西安交通大学医学院第一附属医院 2020-11-10 — — CN disclosed
EP-2493913-B1 HIGH STABILITY STREPTAVIDIN MUTANT PROTEINS UNIV OXFORD INNOVATION LTD (GB) 2018-04-25 — — EP disclosed
US-20180042983-A1 THERAPEUTIC COMPOSITIONS INCLUDING MITOCHONDRIAL FISSION INHIBITOR PEPTIDES, VARIANTS THEREOF, AND METHODS OF USING THE SAME STEALTH PEPTIDES INTERNATIONAL, INC. (MC) 2018-02-15 — — US disclosed
EP-3256143-A2 THERAPEUTIC COMPOSITIONS INCLUDING MITOCHONDRIAL FISSION INHIBITOR PEPTIDES, VARIANTS THEREOF AND METHODS OF USING THE SAME Stealth Peptides International, Inc. (MC) 2017-12-20 — — EP disclosed
WO-2016130143-A2 THERAPEUTIC COMPOSITIONS INCLUDING MITOCHONDRIAL FISSION INHIBITOR PEPTIDES, VARIANTS THEREOF AND METHODS OF USING THE SAME STEALTH PEPTIDES INTERNATIONAL, INC. (MC) 2016-08-18 — — WO disclosed
US-8759488-B2 High stability streptavidin mutant proteins ISIS INNOVATION LIMITED (GB) 2014-06-24 — — US disclosed
EP-2493913-A1 HIGH STABILITY STREPTAVIDIN MUTANT PROTEINS Isis Innovation Limited (GB) 2012-09-05 — — EP disclosed
US-20120214970-A1 High Stability Streptavidin Mutant Proteins OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2012-08-23 — — US disclosed
WO-2011051680-A1 HIGH STABILITY STREPTAVIDIN MUTANT PROTEINS ISIS INNOVATION LIMITED (GB) 2011-05-05 — — WO disclosed
US-5786428-A POLYMER MATRIX OF UNSATURATED MONOMER AND METAL COMPLEX HAVING A LIGAND AND A POLYMERIZABLE UNSATURATED MOIETY; EFFICIENT, RAPID AND SIMPLE PURIFICATION; MEDICAL DIAGNOSIS; CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 1998-07-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180042983-A1 THERAPEUTIC COMPOSITIONS INCLUDING MITOCHONDRIAL FISSION INHIBITOR PEPTIDES, VARIANTS THEREOF, AND METHODS OF USING THE SAME FIS1, DNM1L, RHOT2 RAB9A 764/4885SMN1; SMN2 1255/4885GAA 1016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.